CoChat

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

The prevalence of obesity and diabetes is an increasing global problem, especially in developed countries, and is referred to as the twin epidemics. As such, advanced treatment approaches are needed. Tirzepatide, known as a ‘twincretin’, is a ‘first-in-class’ and the only dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can significantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight by more than 20% and improving lipid metabolism. This novel anti-diabetic drug is a synthetic peptide analog of the human GIP hormone with a C20 fatty-diacid portion attached which, via acylation technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous injection, once a week, which is appropriate to its a half-life of about five days. Tirzepatide, developed by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug Administration in May 2022. This started the ‘twincretin’ era of enormously important and appealing dual therapeutic options for diabetes and obesity, as well as advanced management of closely related cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality worldwide. Herein, we present the key characteristics of tirzepatide in terms of synthesis, structure, and activity, bearing in mind its advantages and shortcomings. Furthermore, we briefly trace the evolution of this kind of medical agent and discuss the development of clinical studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/molecules27134315

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Role of GLP-1 in glucose metabolism.
Figure 1 Role of GLP-1 in glucose metabolism.CC BY · PubMed Central
Figure 2 Structural features of tirzepatide, amino acids are denoted as single-letter codes.
Figure 2 Structural features of tirzepatide, amino acids are denoted as single-letter codes.CC BY · PubMed Central
Figure 3 Fragments used to synthesize tirzepatide using the SPPS/LPPS approach.
Figure 3 Fragments used to synthesize tirzepatide using the SPPS/LPPS approach.CC BY · PubMed Central
Figure 4 Mechanisms of action of tirzepatide within the human body.
Figure 4 Mechanisms of action of tirzepatide within the human body.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Egbuna, C., Kumar, S., Ifemeje, J.C., Ezzat, S.M., and Kaliyaperumal, S. (2020). Chapter 8—Antidiabetic Lead Compounds and Targets for Drug Development. Phytochemicals as Lead Compounds for New Drug Discovery, Elsevier.

Cited by

See all 208

Metadata

Authors
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V.
Affiliations
  • Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad 380009, India
  • Department of Pharmaceutics Analysis and Quality Assurance, LM College of Pharmacy, Ahmedabad 380009, India
  • Department of Pharmaceutical Chemistry, LM College of Pharmacy, Ahmedabad 380009, India
  • Lodz University of Technology (PL)
  • Australian Institute for Musculoskeletal Science (AU)
Corresponding author
  • Chavda, Vivek P.
  • Bojarska, Joanna
  • Apostolopoulos, Vasso
Venue
Molecules
Publisher
MDPI AG
Published
2022-07-05
Volume
27
Issue
13
Pages
4315
ISSN
1420-3049 (ISSN-L)
OpenAlex
W4283834854
Cited by
208
References
57
Citations by year
2026: 40 · 2025: 59 · 2024: 49 · 2023: 49 · 2022: 11
FWCI
5.98
Type
journal article
Language
en
Open access
Locations
  • Molecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Victoria University Research Repository (Victoria University) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
tirzepatide, GIP/GLP-1 receptor agonist, type 2 diabetes, obesity, glycemic control, insulin sensitivity, weight loss, lipid metabolism, albumin binding, acylation, Mounjaro, cardiometabolic disease, drug development
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.